A CGRP receptor antagonist peptide formulated for nasal administration to treat migraine.
Bengt von MentzerAndrew F RussoZhongming ZhangAdisa KuburasPatrick M KilloranVera D'AloisioLaura NizicVicky CapelDavid A KendallChristopher R CoxonGillian A HutcheonPublished in: The Journal of pharmacy and pharmacology (2020)
(34 Pro,35 Phe)CGRP27-37 is a potent CGRP receptor antagonist both in vitro and in vivo, and it can be formulated as a dry powder with no loss of activity indicating its potential as a nasally formulated anti-migraine medicine.
Keyphrases